40 results on '"Buffardi, Salvatore"'
Search Results
2. Prospective Evaluation of Different Methods for Volumetric Analysis on [18F]FDG PET/CT in Pediatric Hodgkin Lymphoma
3. Quantitative Plasma Proteomics to Identify Candidate Biomarkers of Relapse in Pediatric/Adolescent Hodgkin Lymphoma
4. Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia
5. Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real‐life study
6. Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience
7. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma
8. Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience
9. Ileal inflammatory pseudotumor in adolescent male patient with prior Burkitt lymphoma: A challenging diagnosis
10. Proteomic Exploration of Plasma Exosomes and Other Small Extracellular Vesicles in Pediatric Hodgkin Lymphoma: A Potential Source of Biomarkers for Relapse Occurrence
11. HL-032: Nivolumab and Brentuximab Vedotin (BV)–Based, Response-Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study
12. Comparison of Hodgkin’s Lymphoma in Children and Adolescents. A Twenty Year Experience with MH’96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols
13. Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.
14. Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma
15. Minimal residual disease analysis in childhood mature B‐cell leukaemia/lymphoma treated with AIEOP LNH‐97 protocol with/without anti‐CD20 administration
16. Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents and Young Adults (CAYA) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): CheckMate 744 Subgroup Analyses
17. Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma
18. A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma
19. Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma
20. Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience
21. Linfoma di Hodgkin e sindrome nefrosica: un raro caso in età pediatrica
22. Il ruolo dell'imaging nel linfoma di Hodgkin in età pediatrica: stato dell'arte
23. Proteomic Identification of Plasma Biomarkers in Children and Adolescents with Recurrent Hodgkin Lymphoma
24. HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma
25. Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol
26. The prognostic value of biological markers in paediatric Hodgkin lymphoma
27. Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma
28. Long‐term results of the AIEOP LNH‐97 protocol for childhood lymphoblastic lymphoma
29. Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate
30. Mental retardation, congenital heart malformation, and myelodysplasia in a patient with a complex chromosomal rearrangement involving the critical region 21q22
31. Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin’s disease
32. Minimal Disseminated Disease in High-Risk Burkitt's Lymphoma Identifies Patients With Different Prognosis
33. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution
34. Minimal Disseminated Disease Is An Independent Poor Prognosis Marker Among High Risk Burkitt's Lymphoma Patients .
35. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: Experience of two pediatric institutions
36. Prognostic Role of Minimal Residual Disease in Mature B-Cell Acute Lymphoblastic Leukemia of Childhood
37. Fungal Infections in Children With Cancer
38. Hb VILA REAL [β36(C2)Pro → His] IN ITALY: CHARACTERIZATION OF THE AMINO ACID SUBSTITUTION AND THE DNA MUTATION
39. IDENTIFICATION OF Hb VILLEJUIF [β123(H1)Thr→Ile] IN SOUTHERN ITALY
40. Abnormal QT Dispersion Predicts Unexpected Sudden Death in Young Patients with Thalassemia Major
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.